Fady Ibraham Malik sold $371k of CYTK
EVP Research & Development at CYTOKINETICS INC. 6,342 shares at an average of $58.48, traded Nov 12, 2024, filed Nov 13, 2024.
Score components
- +15RoleOfficer
- +15Trade size$371k at market
- 0Share of holdings soldSold 5.3% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -13.1%, 3m -24.6%, 6m -46.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001127602-24-027240, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 12, 2024 | MOption exercise Common Stock10b5-1 | +5,300 | $7.96 | $42k | 120,220 | Nov 13, 2024 |
| Nov 12, 2024 | SOpen-market sale Common Stock10b5-1 | -5,300 | $58.48 | $310k | 114,920 | Nov 13, 2024 |
| Nov 12, 2024 | SOpen-market sale Common Stock10b5-1 | -1,042 | $58.48 | $61k | 113,878 | Nov 13, 2024 |
| Nov 12, 2024 | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -5,300 | $0.00 | $0 | 10,600 | Nov 13, 2024 |
Related signals
Other insiders at CYTOKINETICS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | CYTOKINETICS INC | Fady Ibraham Malik EVP Research & Development | $215k 3,500 shares | -2% | |
| 23Weak | CYTOKINETICS INC | Robert I Blum President & CEO | $491k 7,500 shares | -3% | |
| 8Weak | CYTOKINETICS INC | Fady Ibraham Malik EVP Research & Development | $239k 3,500 shares | -2% | |
| 40Moderate | CYTOKINETICS INC | Robert I Blum President & CEO | $7.3M 105,426 shares | -27% | |
| 23Weak | CYTOKINETICS INC | Robert E Landry director | $72k 1,000 shares | -11% | |
| 18Weak | CYTOKINETICS INC | Robert E Landry director | $75k 1,000 shares | -10% | |
| 8Weak | CYTOKINETICS INC | Fady Ibraham Malik EVP Research & Development | $264k 3,500 shares | -2% | |
| 35Weak | CYTOKINETICS INC | B Lynne Parshall director | $357k 5,000 shares | -32% | |
| 16Weak | CYTOKINETICS INC | Robert I Blum President & CEO | $169k 5,000 shares | -1% | |
| 16Weak | CYTOKINETICS INC | Robert I Blum President & CEO | $156k 5,000 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.